Related LncRNAs |
ID |
lncRNA Name |
Disease |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
Source |
EL0034 |
AF070632 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
down-regulated |
expression |
We noted that LINC01419 was characterized by a significant increase in transcript expression from dysplasia to early HCC. The lncRNA AK021443 was also up-regulated in advanced HCC samples when compared with early HCC. Moreover, expression of LINC01419 and AK021443 was up-regulated in HCC tissues when compared with non-tumor liver tissue. AF070632 expression was down-regulated in HCC and was decreased in advanced HCC when compared with early HCC. These results suggest that LINC01419 may be related to the initiation of HCC, whereas AK021443 and AF070632 may be associated with the progression of HCC. |
26540467 |
Lnc2Cancer
|
EL0040 |
AFAP1-AS1 |
hepatocelluar carcinoma |
real-time PCR; MTT assay |
78 HCC tissues |
up-regulated |
N/A |
AFAP1-AS1 was significantly correlated with pathological staging |
26892468 |
|
EL0044 |
Airn |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
Up regulation in liver by DDC (Diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate ). Furthermore, over expression of H19 and AIR was demonstrated in tumors formed in mice withdrawn for 9 months. |
19362547 |
LncRNADisease
|
EL0051 |
AK056988 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
down-regulated |
N/A |
The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. |
25025236 |
Lnc2Cancer
|
EL0054 |
AK093543 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
down-regulated |
N/A |
To validate the microarray analysis results, five lncRNAs were randomly selected from the differential lncRNAs and their expressions were analyzed using qPCR in 29 pairs of HCC and matched NT tissues. Our data indicated that the expressions of TCONS_00018278, AK093543, D16366 and ENST00000501583 were significantly downregulated in HCC, whereas the expression of NR_002819 showed no significant difference. |
24876753 |
Lnc2Cancer
|
EL0058 |
AK123790 |
hepatocelluar carcinoma |
microarray, qPCR, RIP, RNA pulldown assay etc. |
HCC tissue |
down-regulated |
N/A |
AY129027, uc002pyc and DQ786243 were over-expressed in HCC, whereas the expression of AK055007 and AK123790 was decreased. |
21769904 |
Lnc2Cancer
|
EL0076 |
AOC4P |
hepatocelluar carcinoma |
qPCR, Western blot, RNA pulldown assay, knockdown, |
HCC tissue, cell lines (J7 and SK-Hep1) |
down-regulated |
interaction |
we identified a differentially expressed novel tumor suppressive lncRNA termed amine oxidase, copper containing 4, pseudogene (AOC4P). The level of AOC4P expression was significantly downregulated in 68% of HCC samples and negatively correlated with advanced clinical stage, capsule invasion and vessel invasion. Low AOC4P expression correlated with poor prognostic outcomes, serving as an independent prognostic factor for HCC. In vitro functional assays indicated that AOC4P overexpression significantly reduced cell proliferation, migration and invasion by inhibiting the epithelial-mesenchymal transition (EMT) |
26160837 |
Lnc2Cancer
|
EL0218 |
AX800134 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
down-regulated |
expression |
We determined that a panel based on the expression of uc001ncr and AX800134 accurately diagnosed HBV-positive HCC (AUC values of 0.9494 and 0.9491 for the training and validation cohorts, respectively). The diagnostic performance of the panel remained high in patients with AFP>=400 ng/ml (AUC values of 0.9371 and 0.9527 for the training and validation cohorts, respectively). The panel also diagnosed early HCC (AUC values of 0.9450 and 0.9564 for the training and validation cohorts, respectively) |
26674525 |
Lnc2Cancer
|
EL0230 |
BC014579 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
up-regulated |
expression |
We found that the expression of 7 lncRNAs in preneoplastic lesions and HCC was significantly different. |
26540467 |
Lnc2Cancer
|
EL0231 |
BC017743 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
up-regulated |
N/A |
The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. |
25025236 |
Lnc2Cancer
|
EL0255 |
C14orf132 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
cell lines (Hep3B, HepG2, SMMC-7721, MHCC-97L, MHCC-97H, HCCLM3 etc.) |
down-regulated |
expression |
The most upregulated lncRNAs in H2 were RP11-672F9.1, RP5-1014O16.1, and RP11-501G6.1, while the most downregulated ones were lincRNA-TSPAN8, lincRNA-CALCA, C14orf132, NCRNA00173, and CR613944. We demonstrated that a large number of lncRNAs may play important roles in driving HCC cells to metastasize to different sites; these lncRNAs may provide novel molecular biomarkers and offer a new basis for combating metastasis in HCC cases. |
25556502 |
Lnc2Cancer
|
EL0276 |
CCAT1 |
hepatocelluar carcinoma |
qPCR etc. |
HCC tissue, cell lines (L-02, HepG2, SNU423, SMMC-7721, Hep3B) |
up-regulated |
expression |
The results indicated that the expression of CCAT1 was significantly increased in HCC tissues and cells compared with controls. We also found that the abnormally expressed CCAT1 could promote cell proliferation, migration and invasion. Taken together, our findings demonstrated that the aberrant expression of CCAT1 promotes hepatocellular carcinoma in vitro |
26191246 |
Lnc2Cancer
|
EL0276 |
CCAT1 |
hepatocelluar carcinoma |
qPCR etc. |
Liver cancer cell lines (HepG2, Hep3B, SK-HEP1, SMMC7721, MHCC97-L, MHCC97-H, PLC/PRF/5, HCCLM3) |
up-regulated |
expression |
The results showed that CARLo-5 levels were significantly overexpressed in HCC tissues compared to ANLT. Besides, high expression of CARLo-5 was associated with liver cirrhosis (P = 0.001), tumor number (P < 0.001), vascular invasion (P = 0.001), capsular formation (P = 0.014) and Edmondson-Steiner grade (P < 0.001), which proved that CARLo-5 was an independent risk factor for overall survival and disease-free survival. In addition, in highly metastatic HCC cell lines (HCCLM3 and MHCC97-L), CARLo-5 was up-regulated, but in lowly metastatic HCC cell lines (HepG2, SNU387), it showed down-regulated. Besides, by using gain and loss of function experiments in HCC cell lines (HCCLM3 and HepG2), the results showed that CARLo-5 overexpression significantly enhanced cell proliferation, migration and invasion in vitro. Our study also revealed that CARLo-5 was prominently up-regulated in HCC specimens and its high expression was associated with poor prognosis of HCC patients |
26433964 |
Lnc2Cancer
|
EL0289 |
CDKN2B-AS1 |
hepatocelluar carcinoma |
qPCR, knockdown etc. |
HCC tissue, cell lines ((HepG2 etc.) |
up-regulated |
expression |
LncRNA ANRIL expression in HCC tissues was significantly higher than in the adjacent non-tumor tissues (P < 0.05). The expression of lncRNA ANRIL was remarkably associated with the histologic grade and TNM stage of HCC patients (P < 0.05). In addition, HCC patients with higher lncRNA ANRIL expression had significantly poorer overall survival (P < 0.05).Moreover, in vitro assays revealed that the decreased expression of lncRNA ANRIL could suppress the cell proliferation, migration and invasion HCC cells. |
26045820 |
Lnc2Cancer
|
EL0289 |
CDKN2B-AS1 |
hepatocelluar carcinoma |
qPCR, Western blot, knockdown, RIP etc. |
HCC tissue, cell lines (HepG2, Hep3B, MHCC-97H) |
up-regulated |
interaction |
ANRIL expression was up-regulated in HCC tissues, and the higher expression of ANRIL was significantly correlated with tumor size and Barcelona Clinic Liver Cancer (BCLC) stage. Moreover, taking advantage of loss of function experiments in HCC cells, we found that knockdown of ANRIL expression could impair cell proliferation and invasion and induce cell apoptosis both in vitro and in vivo. |
25966845 |
Lnc2Cancer
|
EL0302 |
CR613944 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
cell lines (Hep3B, HepG2, SMMC-7721, MHCC-97L, MHCC-97H, HCCLM3 etc.) |
down-regulated |
expression |
The most upregulated lncRNAs in H2 were RP11-672F9.1, RP5-1014O16.1, and RP11-501G6.1, while the most downregulated ones were lincRNA-TSPAN8, lincRNA-CALCA, C14orf132, NCRNA00173, and CR613944. We demonstrated that a large number of lncRNAs may play important roles in driving HCC cells to metastasize to different sites; these lncRNAs may provide novel molecular biomarkers and offer a new basis for combating metastasis in HCC cases. |
25556502 |
Lnc2Cancer
|
EL0308 |
CTB-167B5.2 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
down-regulated |
expression |
We found that the expression of 7 lncRNAs in preneoplastic lesions and HCC was significantly different. |
26540467 |
Lnc2Cancer
|
EL0325 |
CYTOR |
hepatocelluar carcinoma |
microarray, qPCR, Western blot, Luciferase reporter assay etc. |
HCC tissue, cell lines ( HepG2, Hep3B, SNU-423 cells. Huh7, L02, SMMC-7721, MHCC-97H) |
up-regulated |
interaction |
Here, based on the increased level of LINC00152 in HCC tissues, we found that LINC00152 could promote cell proliferation in vitro and tumor growth in vivo. Furthermore, microarray-based analysis indicated that LINC00152 could activate the mechanistic target of rapamycin(mTOR) pathway by binding to the promoter of EpCAM through a cis-regulation, as confirmed by Gal4-N/BoxB reporter system. |
26540343 |
Lnc2Cancer
|
EL0325 |
CYTOR |
hepatocelluar carcinoma |
qPCR etc. |
blood (plasma), HCC tissue |
up-regulated |
expression |
Circulating HULC and Linc00152 were significantly up-regulated in plasma samples of HCC patients during training set and validation set. |
26356260 |
Lnc2Cancer
|
EL0329 |
DANCR |
hepatocelluar carcinoma |
qPCR etc. |
HCC cell lines |
up-regulated |
interaction |
We found that lncRNA-DANCR is over-expressed in stem-like HCC cells and this can serve as a prognostic biomarker for HCC patients. Experiments showed that DANCR markedly increased stemness features of HCC cells to promote tumorigenesis and intra-/extra-hepatic tumor colonization.Our studies reveal a significance and mechanism of DANCR action in increasing stemness features and offer a potential prognostic marker and a therapeutic target for HCC. |
25964079 |
Lnc2Cancer
|
EL0333 |
DBH-AS1 |
hepatocelluar carcinoma |
qPCR, Western blot, knockdown etc. |
HCC tissue, cell lines (HepG2, SMMC-7721, Hep3B, MHCC97H, SK-Hep1) |
up-regulated |
interaction |
The levels of DBH-AS1 were positively correlated with hepatitis B surface antigen (HBsAg) and tumor size in HCC tissues. Overexpression of DBH-AS1 induced cell cycle progression by accelerating G1/S and G2/M transition concomitantly with upregulation of CDK6, CCND1, CCNE1 and downregulation of p16, p21 and p27. We also provide evidence that DBH-AS1 could be significantly induced by HBx protein and markedly down-regulated by p53. Thus, we concluded that DBH-AS1 can be induced by HBx and inactivated by p53, and consequently promote cell proliferation and cell survival through activation of MAPK signaling in HCC. |
26393879 |
Lnc2Cancer
|
EL0355 |
DQ786243 |
hepatocelluar carcinoma |
microarray, qPCR, RIP, RNA pulldown assay etc. |
HCC tissue |
up-regulated |
N/A |
AY129027, uc002pyc and DQ786243 were over-expressed in HCC, whereas the expression of AK055007 and AK123790 was decreased. |
21769904 |
Lnc2Cancer
|
EL0357 |
Dreh |
hepatocelluar carcinoma |
microarray, qPCR, in vitro knockdown, RIP etc. |
HCC tissue |
down-regulated |
N/A |
We identified an lncRNA, down-regulated expression by HBx (termed lncRNA-Dreh), which can inhibit HCC growth and metastasis in vitro and in vivo, act as a tumor suppressor in the development of HBV-HCC. LncRNA-Dreh could combine with the intermediate filament protein vimentin and repress its expression, further change the normal cytoskeleton structure to inhibit tumor metastasis. |
23239537 |
Lnc2Cancer
|
EL0357 |
Dreh |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
regulation |
Further experiments showed that Dreh can specifically bind to vimentin, a type III intermediate filament and the major cytoskeletal component of mesenchymal cells and then inhibit HCC metastasis by modifying the expression and reorganization of vimentin. |
24296588 |
LncRNADisease
|
EL0357 |
Dreh |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
regulation |
lncRNA-Dreh could bind to the intermediate filament protein vimentin, repress its expression, and thus change the cytoskeleton structure and inhibit tumor metastasis. It acts as a tumor suppressor in the development of HBV-HCC, which inhibits HCC growth and metastasis?in vitro?and?in vivo. These findings support a role of lncRNA-Dreh in tumor suppression and survival prediction of HCC patients. |
24757675 |
LncRNADisease
|
EL0365 |
EGFR-AS1 |
hepatocelluar carcinoma |
microarray, qPCR, Western blot, knockdown, FCA etc. |
HCC tissue, cell lines of (SMMC-7721, LM-9, Huh-7, HepG2) |
up-regulated |
interaction |
It was verified that EGFR and EGFR-AS1 were relatively upregulated in HCC tissue, and they were significantly related to some clinical characteristics and patient prognosis. Furthermore, EGFR-AS1 was determined to promote HCC development by improving the ability of invasion and proliferation of HCC cells in vitro, and it was also found to affect the cell cycle. Our study identified that EGFR-AS1 may promote HCC genesis and development. EGFR-AS1 may act as a prognostic factor in HCC. |
26271667 |
Lnc2Cancer
|
EL0447 |
ENST00000395084 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
up-regulated |
N/A |
The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. |
25025236 |
Lnc2Cancer
|
EL0464 |
ENST00000501583 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
down-regulated |
N/A |
To validate the microarray analysis results, five lncRNAs were randomly selected from the differential lncRNAs and their expressions were analyzed using qPCR in 29 pairs of HCC and matched NT tissues. Our data indicated that the expressions of TCONS_00018278, AK093543, D16366 and ENST00000501583 were significantly downregulated in HCC, whereas the expression of NR_002819 showed no significant difference. |
24876753 |
Lnc2Cancer
|
EL0489 |
FAM83A-AS1 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
down-regulated |
N/A |
The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. |
25025236 |
Lnc2Cancer
|
EL0507 |
FOSB |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
down-regulated |
N/A |
To validate the microarray analysis results, five lncRNAs were randomly selected from the differential lncRNAs and their expressions were analyzed using qPCR in 29 pairs of HCC and matched NT tissues. Our data indicated that the expressions of TCONS_00018278, AK093543, D16366 and ENST00000501583 were significantly downregulated in HCC, whereas the expression of NR_002819 showed no significant difference. |
24876753 |
Lnc2Cancer
|
EL0514 |
FTX |
hepatocelluar carcinoma |
HCC tissues and cells; clinical analysis |
HCC tissues and cells |
up-regulated |
N/A |
pathway lncRNA Ftx/miR-545/RIG-I promotes HCC development by activating PI3K/Akt signaling |
26992218 |
|
EL0514 |
FTX |
hepatocelluar carcinoma |
N/A |
HBV-related HCC tissue |
up-regulated |
expression |
The overexpression of miR-545/374a cluster located in the Ftx lncRNA is partially responsible for a poor prognosis, and monitoring sera levels of miR-545/374a may be a useful diagnostic marker for HCC. |
25299640 |
|
EL0526 |
GAS5 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HBV-related HCC tissue |
up-regulated |
expression |
Four upregulated lncRNAs were randomly selected and analyzed for their expression levels in tissue samples from 14 HBV-related HCC patients. The corresponding non-tumor tissues were analyzed via qPCR, in which the obtained results are consistent with the microarray data. |
26109807 |
Lnc2Cancer
|
EL0526 |
GAS5 |
hepatocelluar carcinoma |
qPCR etc. |
HCC tissue |
down-regulated |
expression |
The expression level of GAS5 was reduced in HCC in comparison to normal matched tissues (P < 0.05). It is also proved that GAS5 expression was to be associated with HCC tumor size, lymphnode metastasis and clinical stage (P < 0.05). In addition, the Kaplan-Meier survival curves revealed that low GAS5 expression was associated with poor prognosis in HCC patients. GAS5 expression was an independent prognostic marker of overall HCC patient survival in a multivariate analysis. |
25120813 |
Lnc2Cancer
|
EL0526 |
GAS5 |
hepatocelluar carcinoma |
qPCR, Western blot, Luciferase reporter assay, knockdown etc. |
cell lines (Sk-Hep-1, BEL-7404, Huh7) |
up-regulated |
expression |
rs145204276 may contribute to hepatocarcinogenesis by affecting methylation status of the GAS5 promoter and subsequently its transcriptional activity thus serving as a potential therapy target for HCC. |
26163879 |
Lnc2Cancer
|
EL0526 |
GAS5 |
hepatocelluar carcinoma |
qPCR, Western blot, Luciferase reporter assay, knockdown, RIP etc. |
HCC tissue, cell lines (Bel-7402, SMMC-7721, HCCLM3 etc.) |
down-regulated |
interaction |
The present report demonstrates that there are lower levels of GAS5, PDCD4, and PTEN and higher levels of microRNA-21 (miR-21) in HCC tissues than in adjacent normal tissues. Then, overexpression of GAS5 suppresses the migration and invasion of HCC cells and high expression of miR-21 largely eliminates GAS5-mediated suppression of HCC cell migration and invasion. |
26404135 |
Lnc2Cancer
|
EL0526 |
GAS5 |
hepatocelluar carcinoma |
Quantitative polymerase chain reaction and in situ hybridization |
Hepatocellular carcinoma (HCC) tissues |
down-regulated |
interaction |
Overexpression of GAS5 significantly suppressed the proliferation and invasion of hepatoma cells in vitro, promoted the apoptosis of hepatoma cells. |
26707238 |
|
EL0556 |
H19 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
up-regulated |
expression |
We found that imbalances in levels of IGF2 and H19 transcripts were correlated with advanced tumor stage and poor outcome in HCC patients. |
15736456 |
LncRNADisease Lnc2Cancer
|
EL0556 |
H19 |
hepatocelluar carcinoma |
microarray, qPCR, knockdown, ISH etc. |
cell lines (T24P, HepG2, Hep3B etc.) |
up-regulated |
N/A |
The H19 non-coding RNA is essential for human tumor growth. |
17786216 |
LncRNADisease Lnc2Cancer
|
EL0556 |
H19 |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
Dysregulation and functional roles of lncRNAs in HCC |
24183851 |
LncRNADisease
|
EL0556 |
H19 |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
Overexpression of H19 was found in hepatocellular carcinoma.? |
24757675 |
LncRNADisease
|
EL0556 |
H19 |
hepatocelluar carcinoma |
qPCR etc. |
cell lines (SMMC-7721, HepG2) |
up-regulated |
N/A |
Comparing with respective normal cell line, H19 was found highly expressed in stomach cancer cell lines (AGS, MGC-803 and SGC-7901) and hepatocellular carcinoma cell lines (SMMC-7721 and HepG2), while lowly expressed in lung cancer cell line (A549) and prostate cancer cell lines (Du-145 and PC-3). |
24063685 |
Lnc2Cancer
|
EL0556 |
H19 |
hepatocelluar carcinoma |
qPCR, Western blot, knockdown etc. |
cell lines (HepG2) |
up-regulated |
N/A |
We found that AFB1 could up-regulate the expression of H19 and promote cell growth and invasion by hepatocellular carcinoma HepG2 cells. AFB1 induced the expression of E2F1 and its knock-down could down-regulate H19 expression and suppress cell growth and invasion in hepatocellular carcinoma HepG2 cells. E2F1 over-expression could up-regulate H19 expression and promote cell growth and invasion, with binding to the H19 promoter being demonstrated by chromatin immunoprecipitation assays. |
24761865 |
Lnc2Cancer
|
EL0556 |
H19 |
hepatocelluar carcinoma |
qPCR, Western blot, knockdown etc. |
cell lines (Huh-7, MHCC-97H, HepG2 etc.) |
up-regulated |
N/A |
The expression levels of LncRNAH19 and miR-675 were higher in MHCC-97H cells than in L02, Huh-7 and HepG2 cells. Transwell migration assay revealed that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the migration of HCC cells as compared with the control group. Transwell invasion assay demonstrated that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the invasion of HCC cells as compared with the control group. Inhibition of LncRNAH19 and miR-675 expression can promote migration and invasion of HCC cells via AKT/GSK-3β/Cdc25A signaling pathway. |
24939300 |
Lnc2Cancer
|
EL0556 |
H19 |
hepatocelluar carcinoma |
qPCR, Western bolt, Northern bolt, in vitro knockdown, RIP etc. |
HCC tissue, cell lines(SMMC7721, HCCLM3) |
down-regulated |
regulation |
Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. |
23222811 |
LncRNADisease Lnc2Cancer
|
EL0565 |
HEIH |
hepatocelluar carcinoma |
microarray, qPCR, RIP, RNA pulldown assay etc. |
HCC tissue, cell lines (Huh7, HepG2) |
up-regulated |
N/A |
The transcript levels of lncRNA-HEIH were higher in HCC tissues (p=0.010) when compared with the corresponding non-tumor liver tissues from the same donor. And we found that patients with high lncRNA-HEIH expression in HCC had significantly worse prognosis than those with low lncRNA-HEIH expression. |
21769904 |
Lnc2Cancer
|
EL0565 |
HEIH |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
Dr. Yang and his colleagues found that one lncRNA, named lncRNA-HEIH, was overexpressed in HCC tissue compared with normal liver tissues using microarray. |
24757675 |
LncRNADisease
|
EL0565 |
HEIH |
hepatocelluar carcinoma |
qPCR, Western blot, knockdown etc. |
cell lines (MHCC97L, HepG2, cHL-7702) |
up-regulated |
expression |
The expression of HEIH and HULC in hepatocellular carcinoma cell line was significantly increased compared with human normal hepatocyte line (P<0.05). The expression of HULC in HepG2 was higher than that in MHCC97L. The over-expression of HULC could enhance proliferation of MHCC97L and HepG2, however, the over-expression of HEIH could not. The over-expression of HULC and HEIH could promote invasion of MHCC97L and HepG2. Invasion of MHCC97L and HepG2 did not have significant change after down-regulating of HEIH and HULC by siRNA. Over-expression of HULC up-regulated the expression of Snail in HepG2. |
26550214 |
Lnc2Cancer
|
EL0567 |
HELLS |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
up-regulated |
expression |
We noted that LINC01419 was characterized by a significant increase in transcript expression from dysplasia to early HCC. The lncRNA AK021443 was also up-regulated in advanced HCC samples when compared with early HCC. Moreover, expression of LINC01419 and AK021443 was up-regulated in HCC tissues when compared with non-tumor liver tissue. AF070632 expression was down-regulated in HCC and was decreased in advanced HCC when compared with early HCC. These results suggest that LINC01419 may be related to the initiation of HCC, whereas AK021443 and AF070632 may be associated with the progression of HCC. |
26540467 |
Lnc2Cancer
|
EL0578 |
HOTAIR |
hepatocelluar carcinoma |
microarray, qPCR, knockdown, Western blot etc. |
cell lines (HepG2 ,Bel-7402) |
up-regulated |
regulation |
Long non-coding RNA HOTAIR promotes cell migration and invasion via down-regulation of RNA binding motif protein 38 in hepatocellular carcinoma cells. |
24663081 |
LncRNADisease Lnc2Cancer
|
EL0578 |
HOTAIR |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
Overexpression of the HOTAIR transcript, a cis-lncRNA associated with the HOXD gene cluster, has been associated with hepatocellular carcinoma [32], colorectal cancer [33] and breast cancer [13] by deregulation of HOXD cluster genes |
22817756 |
LncRNADisease
|
EL0578 |
HOTAIR |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
Dysregulation and functional roles of lncRNAs in HCC |
24183851 |
LncRNADisease
|
EL0578 |
HOTAIR |
hepatocelluar carcinoma |
qPCR etc. |
HCC tissue, cell lines (HepG2 cell line) |
up-regulated |
expression |
Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma. |
23292722 |
LncRNADisease Lnc2Cancer
|
EL0578 |
HOTAIR |
hepatocelluar carcinoma |
qPCR, knockdown etc. |
HCC tissue, cell lines (SMMC-7721, HepG2, Hep3B etc.) |
up-regulated |
expression |
Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. |
21327457 |
LncRNADisease Lnc2Cancer
|
EL0578 |
HOTAIR |
hepatocelluar carcinoma |
qPCR, Western blot etc. |
cell lines (HepG2, Bel7404, PLC5, Huh7 etc.) |
up-regulated |
interaction |
We found that Hotair was increased in HCC tissues compared to their adjacent non-tumor tissues and the normal liver tissues. Increased Hotair negatively regulated miR-218 expression in HCC, which might be mediated through an EZH2-targeting-miR-218-2 promoter regulatory axis. Further investigation revealed that Hotair knockdown dramatically inhibited cell viability and induced G1-phase arrest in vitro and suppressed tumorigenicity in vivo by promoting miR-218 expression. |
26024833 |
Lnc2Cancer
|
EL0578 |
HOTAIR |
hepatocelluar carcinoma |
qPCR, Western blot, in vitro knockdown etc. |
cell line (Bel7402) |
up-regulated |
expression |
The HOTAIR gene was significantly overexpressed in HCC tissues compared with adjacent non-tumour tissues. Patients with high HOTAIR gene expression in their tumours had an increased risk of recurrence after hepatectomy. |
22289527 |
LncRNADisease Lnc2Cancer
|
EL0582 |
HOTTIP |
hepatocelluar carcinoma |
dual luciferase reporter gene assays |
HCC tissue specimens, mouse xenograft model |
up-regulated |
interaction |
Tthe miR-192/-204-HOTTIP axis might be an important molecular pathway during hepatic cell tumorigenesis. |
26710269 |
|
EL0582 |
HOTTIP |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
Currently, upregulated HOTTIP and HOXA13 expressions were associated with the prognosis and progression of the hepatocellular carcinoma (HCC). |
24531795 |
LncRNADisease
|
EL0582 |
HOTTIP |
hepatocelluar carcinoma |
qPCR, Luciferase reporter assay etc. |
cell lines (BEL7402, MHCC97H, MHCC97H-Luc) |
up-regulated |
regulation |
In our profiling study, HOTTIP was identified as the most significantly up-regulated lncRNA in human HCCs, even in early stage of HCC formation. HOTTIP is a novel oncogenic lncRNA, which negatively regulated by miR-125b. Overexpression of HOTTIP contributes to hepatocarcinogenesis by regulating the expression of its neighboring protein-coding genes. |
25424744 |
Lnc2Cancer
|
EL0582 |
HOTTIP |
hepatocelluar carcinoma |
qPCR, Western blot, knockdown etc. |
HCC tissue, cell lines (SNU182, SNU449, SNU423, SNU387, SNU475 etc.) |
up-regulated |
expression |
Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. |
24114970 |
LncRNADisease Lnc2Cancer
|
EL0586 |
HOXA13 |
hepatocelluar carcinoma |
qPCR, Western blot, knockdown etc. |
HCC tissue, cell lines (SNU182, SNU449, SNU423, SNU387, SNU475 etc.) |
up-regulated |
expression |
lncRNA HOTTIP / HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. |
24114970 |
LncRNADisease Lnc2Cancer
|
EL0600 |
HULC |
hepatocelluar carcinoma |
microarray, qPCR, knockdown etc. |
cell lines (HepG2, Huh7 etc.) |
up-regulated |
N/A |
The relative expression level of HULC, as determined by qPCR, was about 8-fold higher in HCC samples than in normal liver tissue. Depletion of IGF2BP1 led to an increased HULC half-life and higher steady-state expression levels, indicating a post-transcriptional regulatory mechanism. Importantly, HULC represents the first IGF2BP substrate that is destabilized. To elucidate the mechanism by which IGF2BP1 destabilizes HULC, the CNOT1 protein was identified as a novel interaction partner of IGF2BP1. CNOT1 is the scaffold of the human CCR4-NOT deadenylase complex, a major component of the cytoplasmic RNA decay machinery. Indeed, depletion of CNOT1 increased HULC half-life and expression. Thus, IGF2BP1 acts as an adaptor protein that recruits the CCR4-NOT complex and thereby initiates the degradation of the lncRNA HULC. |
23728852 |
Lnc2Cancer
|
EL0600 |
HULC |
hepatocelluar carcinoma |
microarray, qPCR, Northern blot, ISH, knockdown etc. |
HCC tissue, blood |
up-regulated |
expression |
Highly up-regulated in liver cancer. |
17241883 |
LncRNADisease Lnc2Cancer
|
EL0600 |
HULC |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
A similar genome-wide differential expression screen in hepatocellular carcinoma (HCC) has uncovered another cancer-associated lncRNA, Highly Upregulated in Liver Cancer, or HULC. |
20951849 |
LncRNADisease
|
EL0600 |
HULC |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
The lncRNA HULC is one of the most upregulated of all genes in hepatocellular carcinoma. |
21802130 |
LncRNADisease
|
EL0600 |
HULC |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
Dysregulation and functional roles of lncRNAs in HCC |
24183851 |
LncRNADisease
|
EL0600 |
HULC |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
regulation |
Here we focus on two best-characterized lncRNAs-HULC and LALR, which can impact proliferation through targeting various key regulators in different pathways. |
24296588 |
LncRNADisease
|
EL0600 |
HULC |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
regulation |
Moreover, HULC correlated with upregulated hepatitis B virus X protein (HBx) that importantly contributes to HCC and that was able to promote HULC expression. The HULC-mediated downregulation of the tumor suppressor p18 supported the HCC proliferation. |
24531795 |
LncRNADisease
|
EL0600 |
HULC |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
regulation |
A lncRNA, highly upregulated in liver cancer (HULC), was found to contribute to tumorigenesis of HCC. |
24757675 |
LncRNADisease
|
EL0600 |
HULC |
hepatocelluar carcinoma |
qPCR etc. |
HCC tissue |
up-regulated |
N/A |
In this study, we demonstrate that HULC expression is significantly higher in HCC tumors compared to normal liver tissues. Among the tumor tissues, higher HULC expression is positively associated with Edmondson histological grades or with hepatitis B (HBV) positive status. Moreover, HULC lncRNA is detected with higher frequency in the plasma of HCC patients compared to healthy controls. Higher HULC detection rates are observed in the plasma of patients with higher Edmondson grades or with HBV+ status. |
23762823 |
Lnc2Cancer
|
EL0600 |
HULC |
hepatocelluar carcinoma |
qPCR etc. |
blood (plasma), HCC tissue |
up-regulated |
expression |
Circulating HULC and Linc00152 were significantly up-regulated in plasma samples of HCC patients during training set and validation set. |
26356260 |
Lnc2Cancer
|
EL0600 |
HULC |
hepatocelluar carcinoma |
qPCR, Western blot, knockdown etc. |
cell lines (MHCC97L, HepG2, cHL-7702) |
up-regulated |
expression |
The expression of HEIH and HULC in hepatocellular carcinoma cell line was significantly increased compared with human normal hepatocyte line (P<0.05). The expression of HULC in HepG2 was higher than that in MHCC97L. The over-expression of HULC could enhance proliferation of MHCC97L and HepG2, however, the over-expression of HEIH could not. The over-expression of HULC and HEIH could promote invasion of MHCC97L and HepG2. Invasion of MHCC97L and HepG2 did not have significant change after down-regulating of HEIH and HULC by siRNA. Over-expression of HULC up-regulated the expression of Snail in HepG2. |
26550214 |
Lnc2Cancer
|
EL0600 |
HULC |
hepatocelluar carcinoma |
qPCR, Western bolt, Luciferase reporter assayRIP etc. |
liver cancer tissue, cell lines (Panc1, MiaPaCa2, Panc28, L3.6pl etc.) |
up-regulated |
N/A |
We found that the expression levels of HULC were positively correlated with those of HBx in clinical HCC tissues. Moreover, we revealed that HBx up-regulated HULC in human immortalized normal liver L-O2 cells and hepatoma HepG2 cells. Luciferase reporter gene assay and chromatin immunoprecipitation (ChIP) assay showed that HBx activated the HULC promoter via cAMP-responsive element-binding protein. We further demonstrated that HULC promoted cell proliferation by methyl thiazolyl tetrazolium, 5-ethynyl-2'-deoxyuridine, colony formation assay, and tumorigenicity assay. Then, we validated that HULC down-regulated p18, which was involved in the HULC-enhanced cell proliferation in vitro and in vivo. In a word, HULC play function through regulating a tumor suppressor gene p18 located near HULC in the same chromosome. |
22685290 |
Lnc2Cancer
|
EL0600 |
HULC |
hepatocelluar carcinoma |
TaqMan SNP array etc. |
HCC tissue |
differential expression |
mutation |
We conducted a case-control study and genotyped two SNPs, rs7763881 in HULC and rs619586 in MALAT1 Furthermore, the variant genotypes of rs619586 was associated with decreased HCC risk with a borderline significance. |
22493738 |
LncRNADisease Lnc2Cancer
|
EL0605 |
ICR |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue, cell lines(CSQT-2, Huh7, Hep3B) |
up-regulated |
interaction |
Compared with the corresponding primary tumors, PVTT expressed different lncRNAs and mRNAs, including the up-regulated lncRNA ICR and ICAM-1. ICR regulated ICAM-1 expression by increasing the stability of its mRNA through RNA duplex formation, which modulated the CSC properties of ICAM-1+ HCC cells. ICR transcription in ICAM-1+ HCC cells was regulated by Nanog and inhibition of ICR in situ significantly reduced ICAM-1 expression and ICAM-1+ HCC cells in tumors in vivo. Moreover, elevated ICR and ICAM-1 expression in tumors was correlated with PVTT development and poor clinical outcomes |
26667486 |
Lnc2Cancer
|
EL0608 |
IGF2-AS |
hepatocelluar carcinoma |
qPCR, Southern blot etc. |
SMMC-7721 cell line |
differential expression |
N/A |
IGF-IR and IGF-IIR antisense genes could significantly restrain the malignant behavior of human hepatoma cells and might be useful in investigating a potential route for hepatocellular carcinoma gene therapy. |
12603530 |
LncRNADisease Lnc2Cancer
|
EL0628 |
KCNQ1OT1 |
hepatocelluar carcinoma |
qPCR etc. |
HCC tissue |
differential expression |
mutation |
A novel tetranucleotide repeat polymorphism within KCNQ1OT1 confers risk for hepatocellular carcinoma. |
23984860 |
LncRNADisease Lnc2Cancer
|
EL0638 |
LALR |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
regulation |
Here we focus on two best-characterized lncRNAs-HULC and LALR, which can impact proliferation through targeting various key regulators in different pathways. |
24296588 |
LncRNADisease
|
EL0648 |
LINC00173 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
cell lines (Hep3B, HepG2, SMMC-7721, MHCC-97L, MHCC-97H, HCCLM3 etc.) |
down-regulated |
expression |
The most upregulated lncRNAs in H2 were RP11-672F9.1, RP5-1014O16.1, and RP11-501G6.1, while the most downregulated ones were lincRNA-TSPAN8, lincRNA-CALCA, C14orf132, NCRNA00173, and CR613944. We demonstrated that a large number of lncRNAs may play important roles in driving HCC cells to metastasize to different sites; these lncRNAs may provide novel molecular biomarkers and offer a new basis for combating metastasis in HCC cases. |
25556502 |
Lnc2Cancer
|
EL0676 |
LINC00974 |
hepatocelluar carcinoma |
qPCR, in vitro knockdown, RIP etc. |
HCC tissue, blood(plasma) |
up-regulated |
interaction |
Knockdown of Linc00974 resulted in an inhibition of cell proliferation and invasion with an activation of apoptosis and cell cycle arrest in vitro.The combination of Linc00974 and KRT19 may be novel indices for clinical diagnosis of tumor growth and metastasis in HCC, while Linc00974 may become a potential therapeutic target for the prevention of HCC progression. We also discovered Linc00974F-1 stably expressed in the plasma. |
25476897 |
Lnc2Cancer
|
EL0680 |
LINC01018 |
hepatocelluar carcinoma |
qPCR etc. |
HCC tissue, cell lines (BEL-7402, SK-Hep1, Huh7, MHCC-97H) |
down-regulated |
mutation |
We found that a lower SRHC expression level was significantly more frequent in tissues with a high serum a-fetoprotein level and a low degree of differentiated tumors. Furthermore, we found that the promoter region of SRHC contains a CpG-rich island and that SRHC is down-regulated in tumors by DNA methylation. |
25512078 |
Lnc2Cancer
|
EL0689 |
LINC01225 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
up-regulated |
expression |
We discovered three lncRNA, RP11-160H22.5, XLOC_014172 and LOC149086, which were up-regulated in HCC comparing with the cancer-free controls. RP11-160H22.5, XLOC_014172 and LOC149086 might be the potential biomarker for the tumorigenesis prediction and XLOC_014172 and LOC149086 for metastasis prediction in the future. |
25714016 |
Lnc2Cancer
|
EL0694 |
LINC01419 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HBV-related HCC tissue |
up-regulated |
expression |
Four upregulated lncRNAs were randomly selected and analyzed for their expression levels in tissue samples from 14 HBV-related HCC patients. The corresponding non-tumor tissues were analyzed via qPCR, in which the obtained results are consistent with the microarray data. |
26109807 |
Lnc2Cancer
|
EL0694 |
LINC01419 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
up-regulated |
expression |
We noted that LINC01419 was characterized by a significant increase in transcript expression from dysplasia to early HCC. The lncRNA AK021443 was also up-regulated in advanced HCC samples when compared with early HCC. Moreover, expression of LINC01419 and AK021443 was up-regulated in HCC tissues when compared with non-tumor liver tissue. AF070632 expression was down-regulated in HCC and was decreased in advanced HCC when compared with early HCC. These results suggest that LINC01419 may be related to the initiation of HCC, whereas AK021443 and AF070632 may be associated with the progression of HCC. |
26540467 |
Lnc2Cancer
|
EL0697 |
LINC01451 |
hepatocelluar carcinoma |
microarray, qPCR, RIP, RNA pulldown assay etc. |
HCC tissue |
up-regulated |
N/A |
AY129027, uc002pyc and DQ786243 were over-expressed in HCC, whereas the expression of AK055007 and AK123790 was decreased. |
21769904 |
Lnc2Cancer
|
EL0743 |
lincRNA-CALCA |
hepatocelluar carcinoma |
microarray, qPCR etc. |
cell lines (Hep3B, HepG2, SMMC-7721, MHCC-97L, MHCC-97H, HCCLM3 etc.) |
down-regulated |
expression |
The most upregulated lncRNAs in H2 were RP11-672F9.1, RP5-1014O16.1, and RP11-501G6.1, while the most downregulated ones were lincRNA-TSPAN8, lincRNA-CALCA, C14orf132, NCRNA00173, and CR613944. We demonstrated that a large number of lncRNAs may play important roles in driving HCC cells to metastasize to different sites; these lncRNAs may provide novel molecular biomarkers and offer a new basis for combating metastasis in HCC cases. |
25556502 |
Lnc2Cancer
|
EL0745 |
lincRNA-TSPAN8 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
cell lines (Hep3B, HepG2, SMMC-7721, MHCC-97L, MHCC-97H, HCCLM3 etc.) |
down-regulated |
expression |
The most upregulated lncRNAs in H2 were RP11-672F9.1, RP5-1014O16.1, and RP11-501G6.1, while the most downregulated ones were lincRNA-TSPAN8, lincRNA-CALCA, C14orf132, NCRNA00173, and CR613944. Among them, lincRNA-TSPAN8 and TSPAN8 were found highly expressed in high lung metastatic potential HCC cells, while lowly expressed in no or low lung metastatic potential HCC cells. We demonstrated that a large number of lncRNAs may play important roles in driving HCC cells to metastasize to different sites; these lncRNAs may provide novel molecular biomarkers and offer a new basis for combating metastasis in HCC cases. |
25556502 |
Lnc2Cancer
|
EL0747 |
LINC-ROR |
hepatocelluar carcinoma |
qPCR, Luciferase reporter assays, knockdown etc. |
cell lines (HepG2, PLC-PRF5) |
up-regulated |
N/A |
lincRNA-ROR (linc-ROR), a stress-responsive lncRNA was highly expressed in HCC cells and enriched within extracellular vesicles derived from tumor cells. Incubation with HCC-derived extracellular vesicles increased linc-ROR expression and reduced chemotherapy-induced cell death in recipient cells. Sorafenib increased linc-ROR expression in both tumor cells and extracellular vesicles, whereas siRNA to linc-ROR increased chemotherapy-induced apoptosis and cytotoxicity. |
24918061 |
Lnc2Cancer
|
EL0761 |
lnc-AF085935 |
hepatocelluar carcinoma |
qPCR etc. |
blood (serum) |
up-regulated |
expression |
The level of serum lncRNA-uc003wbd and lncRNA-AF085935 was significantly upregulated in HCC patients and HBV patients compared with that in normal controls.In addition, higher expressions of lncRNAs were observed in HCC patients than in HBV patients. LncRNA-uc003wbd and lncRNA-AF085935 were observed with an aberrant serum level in HCC and HBV patients, which is showing that both lncRNA-uc003wbd and lncRNA-AF085935 are able to be potential biomarkers for HCC and HBV screening. |
25501706 |
Lnc2Cancer
|
EL0799 |
lncRNA-ATB |
hepatocelluar carcinoma |
immunohistochemistry quantitative RT-PCR analysis |
keloid tissue and keloid fibroblasts |
N/A |
N/A |
lncRNA-ATB governs the autocrine secretion of TGF-β2 in KFs |
27090737 |
|
EL0799 |
lncRNA-ATB |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue, cell lines (SMMC-7721) |
up-regulated |
regulation |
Thus, these findings suggest that?lncRNA-ATB, a mediator of TGF-β signaling, could predispose HCC patients to metastases and may serve as a potential target for antimetastatic therapies. |
24768205 |
LncRNADisease Lnc2Cancer
|
EL0809 |
lnc-uc003wbd |
hepatocelluar carcinoma |
qPCR etc. |
blood (serum) |
up-regulated |
expression |
The level of serum lncRNA-uc003wbd and lncRNA-AF085935 was significantly upregulated in HCC patients and HBV patients compared with that in normal controls.In addition, higher expressions of lncRNAs were observed in HCC patients than in HBV patients. LncRNA-uc003wbd and lncRNA-AF085935 were observed with an aberrant serum level in HCC and HBV patients, which is showing that both lncRNA-uc003wbd and lncRNA-AF085935 are able to be potential biomarkers for HCC and HBV screening. |
25501706 |
Lnc2Cancer
|
EL0853 |
MALAT1 |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
HCC and HPBL have clearly different patterns of gene expression, with genes IGF2, Fibronectin, DLK1, TGFb1, MALAT1 and MIG6 being over-expressed in HPBL versus HCC |
17006932 |
LncRNADisease
|
EL0853 |
MALAT1 |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
mutation |
We conducted a case-control study and genotyped two SNPs, rs7763881 in HULC and rs619586 in MALAT1 Furthermore, the variant genotypes of rs619586 was associated with decreased HCC risk with a borderline significance. |
22493738 |
LncRNADisease Lnc2Cancer
|
EL0853 |
MALAT1 |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
Dysregulation and functional roles of lncRNAs in HCC |
24183851 |
LncRNADisease
|
EL0853 |
MALAT1 |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
Overexpressed MALAT1 was found in many solid tumors such as lung cancer, cervical cancer, and HCC. |
24757675 |
LncRNADisease
|
EL0853 |
MALAT1 |
hepatocelluar carcinoma |
qPCR, knockdown etc. |
HCC tissue |
up-regulated |
expression |
Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. |
21678027 |
LncRNADisease Lnc2Cancer
|
EL0853 |
MALAT1 |
hepatocelluar carcinoma |
qPCR, Northern blot, ISH etc. |
HCC tissue, cell line (CT26) |
up-regulated |
expression |
Quantitative analyses indicated a 6-7-fold increased RNA level in HCCs versus uninvolved liver, advancing this as a molecule of interest. |
16878148 |
LncRNADisease Lnc2Cancer
|
EL0861 |
MEG3 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
down-regulated |
expression |
Enforced expression of MEG3 in HCC cells significantly decreased both anchorage-dependent and -independent cell growth, and induced apoptosis. Methylation-dependent tissue-specific regulation of the lncRNA MEG3 by miR-29a may contribute to HCC growth. |
21625215 |
LncRNADisease Lnc2Cancer
|
EL0861 |
MEG3 |
hepatocelluar carcinoma |
N/A |
MS2 virus-like particles (VLPs) crosslinked with GE11 polypeptide |
N/A |
N/A |
N/A |
26992211 |
|
EL0861 |
MEG3 |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
Braconi et al. found that the expression of maternally expressed gene 3 (MEG3) is markedly reduced in four human HCC cell lines compared with normal hepatocytes and enforced expression of MEG3 in HCC cells significantly induce apoptosis. |
24296588 |
LncRNADisease
|
EL0861 |
MEG3 |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
regulation |
Expression of MEG3 in tumor cells results in growth suppression, p53 protein increase, and activation of p53 downstream targets. |
24757675 |
LncRNADisease
|
EL0872 |
MINA |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
Dysfunction of MDIG was found in several types of solid cancers including gastric carcinoma, esophageal squamous cell carcinoma, and lung cancer. Overexpression of MDIG was observed in hepatocellular carcinoma.? |
24757675 |
LncRNADisease
|
EL0882 |
MIR7-3HG |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
Besides, another study showed that liver cancer-downregulated lncRNA uc002mbe.2 could be induced by trichostatin A (TSA) treatment and its expression is positively correlated with the apoptotic effect of TSA in HCC cells. |
24296588 |
LncRNADisease
|
EL0950 |
MVIH |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
regulation |
Dr. Yuan et al. found that lncRNA-MVIH could promote tumor growth and intrahepatic metastasis by contributing to active angiogenesis both?in vitro?and?in vivo?through the inhibition of phosphoglycerate kinase 1 (PGK1) secretion |
24757675 |
LncRNADisease
|
EL0950 |
MVIH |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
Yuan et al discovered that the lncRNA MVIH (long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma) was overexpressed in hepatocellular carcinoma. |
24829860 |
LncRNADisease
|
EL0950 |
MVIH |
hepatocelluar carcinoma |
qPCR etc. |
HCC tissues |
up-regulated |
N/A |
In this study, we found that lncRNA MVIH was generally overexpressed in HCC. In a cohort of 215 HCC patients, the overexpression of MVIH was associated with frequent microvascular invasion and a higher tumor node metastasis stage as well as decreased recurrence-free survival (RFS) and overall survival. We also found that MVIH could promote tumor growth and intrahepatic metastasis by activating angiogenesis in mouse models. Subsequent investigations indicated that MVIH could activate tumor-inducing angiogenesis by inhibiting the secretion of phosphoglycerate kinase 1(PGK1). |
22706893 |
Lnc2Cancer
|
EL0973 |
NEAT1 |
hepatocelluar carcinoma |
qPCR etc. |
HCC tissue |
up-regulated |
interaction |
Our results revealed that NEAT1 appeared to have higher expression in the HCC tissues, compared with the adjacent non-cancerous liver tissues. High levels of NEAT1 promoted the clinical features of HCC, including the number of tumor nodes, metastasis, clinical TNM stage, the status of portal vein tumor embolus, vaso-invasion and the infiltration of tumor cells. Additionally, high NEAT1 expression levels were significantly associated with the expression level of MDTH, NM23 and MALAT1 |
26191242 |
Lnc2Cancer
|
EL1007 |
NPTN-IT1 |
hepatocelluar carcinoma |
microarray, qPCR, RIP, RNA pulldown assay etc. |
HCC tissue |
down-regulated |
N/A |
AY129027, uc002pyc and DQ786243 were over-expressed in HCC, whereas the expression of AK055007 and AK123790 was decreased. |
21769904 |
Lnc2Cancer
|
EL1007 |
NPTN-IT1 |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
Importantly, another lncRNA-LET (lncRNA low expression in tumor) is found to play a critical role in hypoxia-induced metastasis in HCC |
24296588 |
LncRNADisease
|
EL1007 |
NPTN-IT1 |
hepatocelluar carcinoma |
qPCR, Western blot, in vitro knockdown, RIP etc. |
HCC tissue, cell lines (QSG-7701, LO2, SMMC-7721 etc.) |
down-regulated |
expression |
In this study, we found that the lncRNA Low Expression in Tumor (lncRNA-LET) was generally downregulated in hepatocellular carcinomas, colorectal cancers, and squamous-cell lung carcinomas. |
23395002 |
LncRNADisease Lnc2Cancer
|
EL1028 |
P14695 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
primary HCC tissue, cell lines (MHCC97H, MHCC97L) |
up-regulated |
expression |
We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). |
25900874 |
Lnc2Cancer
|
EL1029 |
P16984 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
primary HCC tissue, cell lines (MHCC97H, MHCC97L) |
down-regulated |
expression |
We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). |
25900874 |
Lnc2Cancer
|
EL1030 |
P19780 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
primary HCC tissue, cell lines (MHCC97H, MHCC97L) |
down-regulated |
expression |
We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). |
25900874 |
Lnc2Cancer
|
EL1031 |
P23099 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
primary HCC tissue, cell lines (MHCC97H, MHCC97L) |
up-regulated |
expression |
We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). |
25900874 |
Lnc2Cancer
|
EL1032 |
P24363 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
primary HCC tissue, cell lines (MHCC97H, MHCC97L) |
up-regulated |
expression |
We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). |
25900874 |
Lnc2Cancer
|
EL1033 |
P28210 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
primary HCC tissue, cell lines (MHCC97H, MHCC97L) |
up-regulated |
expression |
We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). |
25900874 |
Lnc2Cancer
|
EL1035 |
P33863 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
primary HCC tissue, cell lines (MHCC97H, MHCC97L) |
down-regulated |
expression |
We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). |
25900874 |
Lnc2Cancer
|
EL1036 |
P4091 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
primary HCC tissue, cell lines (MHCC97H, MHCC97L) |
up-regulated |
expression |
We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). |
25900874 |
Lnc2Cancer
|
EL1037 |
P6391 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
primary HCC tissue, cell lines (MHCC97H, MHCC97L) |
up-regulated |
expression |
We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). |
25900874 |
Lnc2Cancer
|
EL1038 |
P6488 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
primary HCC tissue, cell lines (MHCC97H, MHCC97L) |
down-regulated |
expression |
We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). |
25900874 |
Lnc2Cancer
|
EL1039 |
P700 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
primary HCC tissue, cell lines (MHCC97H, MHCC97L) |
down-regulated |
expression |
We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). |
25900874 |
Lnc2Cancer
|
EL1040 |
P8611 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
primary HCC tissue, cell lines (MHCC97H, MHCC97L) |
down-regulated |
expression |
We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). |
25900874 |
Lnc2Cancer
|
EL1041 |
P8725 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
primary HCC tissue, cell lines (MHCC97H, MHCC97L) |
up-regulated |
expression |
We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). |
25900874 |
Lnc2Cancer
|
EL1042 |
P8860 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
primary HCC tissue, cell lines (MHCC97H, MHCC97L) |
up-regulated |
expression |
We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). |
25900874 |
Lnc2Cancer
|
EL1043 |
P9745 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
primary HCC tissue, cell lines (MHCC97H, MHCC97L) |
up-regulated |
expression |
We randomly selected 15 out of the significantly differentially expressed LncRNAs in P3 and validated their expression levels in cell lines (MHCC97H and MHCC97L). In those LncRNAs, nine of which were upregulated (P23099, P8860, P14695, P28210, P4091, P6391, P24363, P8725, and P9745) and six of which were downregulated (P6488, P700, P8611, P16984, P19780, and P33863). |
25900874 |
Lnc2Cancer
|
EL1046 |
PANDAR |
hepatocelluar carcinoma |
qPCR, knockdown etc. |
HCC tissue, cell lines (HCCLM3, Hep3B, HepG2) |
up-regulated |
expression |
PANDAR was overexpressed in HCC tissues and cell lines. Moreover, its expression level was significantly correlated with liver cirrhosis, HBsAg, AFP, tumor nodule, vascular invasion and TNM stage. PANDAR overexpression was associated with poorer survival and shorter recurrence and served as an independent prognostic marker of patients with HCC. |
26054684 |
Lnc2Cancer
|
EL1052 |
PCAT1 |
hepatocelluar carcinoma |
the reverse transcription-quantitative polymerase chain reaction |
HCC tissue samples and HepG2 and Bel‑7402 cell lines |
up-regulated |
N/A |
Overexpression of PCAT‑1 induced synthetic plasmid vectors |
27035680 |
|
EL1059 |
PCNA-AS1 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
cell lines (Huh7, SMMC7721) |
up-regulated |
regulation |
Antisense long non-coding RNA PCNA-AS1 promotes tumor growth by regulating proliferating cell nuclear antigen in hepatocellular carcinoma. |
24704293 |
LncRNADisease Lnc2Cancer
|
EL1082 |
PRAL |
hepatocelluar carcinoma |
qPCR, Western blot etc. |
hepatocellular carcinoma tissues |
down-regulated |
interaction |
We found that lncRNA-PRAL could inhibit HCC growth and induce apoptosis in vivo and in vitro through p53. Subsequent investigations indicated that the three stem-loop motifs at the 5' end of lncRNA-PRAL facilitated the combination of HSP90 and p53, and thus competitively inhibited the MDM2-dependent p53 ubiquitination, resulting in the enhanced p53 stability. Additionally, in vivo lncRNA-PRAL delivery efficiently reduced the intrinsic tumors, indicating its potential therapeutic application. |
26663434 |
Lnc2Cancer
|
EL1089 |
PRR26 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
down-regulated |
N/A |
The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. |
25025236 |
Lnc2Cancer
|
EL1097 |
PTENP1 |
hepatocelluar carcinoma |
qPCR, Western blot etc. |
HCC cell lines |
down-regulated |
expression |
Here we confirmed that PTENP1 and PTEN were downregulated in several HCC cells.These data colletcively unveiled the molecular mechanisms of how PTENP1 repressed the tumorigenic properties of HCC cells and demonstrated the potential of the SB-BV hybrid vetcor for PTENP1 lncRNA modulation and HCC therapy.PTENP1 repressed the tumorigenic properties of HCC cells and demonstrated the potential of the SB-BV hybrid vector for PTENP1 lncRNA modulation and HCC therapy. |
25617127 |
Lnc2Cancer
|
EL1102 |
PVT1 |
hepatocelluar carcinoma |
qPCR etc. |
cell lines (HepG2, LM3, SMMC-7721) |
up-regulated |
N/A |
Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2 |
25043274 |
LncRNADisease Lnc2Cancer
|
EL1102 |
PVT1 |
hepatocelluar carcinoma |
qPCR etc. |
HCC tissue, cell lines (Huh7, SK-hep1, SMMC-7721, HepG2, Hep3B, PLC/PRF/5, Bel-7402) |
up-regulated |
expression |
The relative expression levels of PVT1 were significantly higher in cancerous tissues compared with the corresponding non-cancerous tissues. Furthermore, overexpression of PVT1 was associated with a higher serum a-fetoprotein expression level and a higher recurrence rate. Kaplan-Meier analysis indicated that the patients with high PVT1 expression exhibited poor recurrence-free survival, and multivariate analysis demonstrated that high levels of PVT1 expression are an independent predictor for HCC recurrence. |
25624916 |
Lnc2Cancer
|
EL1106 |
RAD1 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
up-regulated |
N/A |
The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. |
25025236 |
Lnc2Cancer
|
EL1134 |
LOC102724601 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
up-regulated |
expression |
We discovered three lncRNA, RP11-160H22.5, XLOC_014172 and LOC149086, which were up-regulated in HCC comparing with the cancer-free controls. RP11-160H22.5, XLOC_014172 and LOC149086 might be the potential biomarker for the tumorigenesis prediction and XLOC_014172 and LOC149086 for metastasis prediction in the future. |
25714016 |
Lnc2Cancer
|
EL1143 |
RP11-401P9.4 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
up-regulated |
expression |
We found that the expression of 7 lncRNAs in preneoplastic lesions and HCC was significantly different. |
26540467 |
Lnc2Cancer
|
EL1148 |
LINC00383 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
cell lines (Hep3B, HepG2, SMMC-7721, MHCC-97L, MHCC-97H, HCCLM3 etc.) |
up-regulated |
expression |
The most upregulated lncRNAs in H2 were RP11-672F9.1, RP5-1014O16.1, and RP11-501G6.1, while the most downregulated ones were lincRNA-TSPAN8, lincRNA-CALCA, C14orf132, NCRNA00173, and CR613944. RP5- 1014O16.1 was highly expressed in high lymphatic metastatic potential HCC cell lines, while lowly expressed in no lymphatic metastatic potential HCC cell lines.We demonstrated that a large number of lncRNAs may play important roles in driving HCC cells to metastasize to different sites; these lncRNAs may provide novel molecular biomarkers and offer a new basis for combating metastasis in HCC cases. |
25556502 |
Lnc2Cancer
|
EL1152 |
AL133217.1 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
cell lines (Hep3B, HepG2, SMMC-7721, MHCC-97L, MHCC-97H, HCCLM3 etc.) |
up-regulated |
expression |
The most upregulated lncRNAs in H2 were RP11-672F9.1, RP5-1014O16.1, and RP11-501G6.1, while the most downregulated ones were lincRNA-TSPAN8, lincRNA-CALCA, C14orf132, NCRNA00173, and CR613944. We demonstrated that a large number of lncRNAs may play important roles in driving HCC cells to metastasize to different sites; these lncRNAs may provide novel molecular biomarkers and offer a new basis for combating metastasis in HCC cases. |
25556502 |
Lnc2Cancer
|
EL1164 |
AC244098.1 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
cell lines (Hep3B, HepG2, SMMC-7721, MHCC-97L, MHCC-97H, HCCLM3 etc.) |
up-regulated |
expression |
The most upregulated lncRNAs in H2 were RP11-672F9.1, RP5-1014O16.1, and RP11-501G6.1, while the most downregulated ones were lincRNA-TSPAN8, lincRNA-CALCA, C14orf132, NCRNA00173, and CR613944. We demonstrated that a large number of lncRNAs may play important roles in driving HCC cells to metastasize to different sites; these lncRNAs may provide novel molecular biomarkers and offer a new basis for combating metastasis in HCC cases. |
25556502 |
Lnc2Cancer
|
EL1206 |
SIRT1-AS |
hepatocelluar carcinoma |
qPCR, Western blot, Northern blot, knockdown etc. |
cell line (HCC-9903) |
up-regulated |
interaction |
SIRT1-AS overexpression promoted the proliferation of the human HCC cell lines by upregulating the SIRT1 protein level. The mechanism was that SIRT1-AS bound to SIRT1 mRNA at 3'UTR, masked the miR-29c binding site and stabilized SIRT1 mRNA. |
26324025 |
Lnc2Cancer
|
EL1207 |
SIRT1-AS 622C mutation |
hepatocelluar carcinoma |
qPCR, Western blot, Northern blot, knockdown etc. |
cell line (HCC-9903) |
up-regulated |
mutation |
The mutation led to a marked alteration in the secondary structure of SIRT1-AS and caused its inability to bind with SIRT1 mRNA. |
26324025 |
Lnc2Cancer
|
EL1227 |
SNHG19 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
up-regulated |
expression |
We found that the expression of 7 lncRNAs in preneoplastic lesions and HCC was significantly different. |
26540467 |
Lnc2Cancer
|
EL1228 |
SNHG3 |
hepatocelluar carcinoma |
RNA-seq, qPCR, ISH etc. |
HCC tissue |
up-regulated |
expression |
Our results showed that the expression level of SNHG3 was significantly upregulated in HCC tissues compared with paired noncancerous tissues from 51 HCC patients, increased SNHG3 expression is associated with malignant status and poor prognosis in HCC patients. |
26373735 |
Lnc2Cancer
|
EL1236 |
SOX2-OT |
hepatocelluar carcinoma |
qPCR, knockdown etc. |
HCC tissue, cell lines (HepG2, SMMC-7721) |
up-regulated |
expression |
lncRNA Sox2ot expression level was significantly higher in HCC tissues compared with adjacent non-tumor tissues. High expression of lncRNA Sox2ot was associated with histological grade, TNM stage, and vein invasion. |
26097588 |
Lnc2Cancer
|
EL1283 |
TCONS_00018278 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
down-regulated |
N/A |
To validate the microarray analysis results, five lncRNAs were randomly selected from the differential lncRNAs and their expressions were analyzed using qPCR in 29 pairs of HCC and matched NT tissues. Our data indicated that the expressions of TCONS_00018278, AK093543, D16366 and ENST00000501583 were significantly downregulated in HCC, whereas the expression of NR_002819 showed no significant difference. |
24876753 |
Lnc2Cancer
|
EL1349 |
TP53COR1 |
hepatocelluar carcinoma |
qPCR, Western blot, knockdown etc. |
hepatocellular cancer tissue |
down-regulated |
expression |
We demonstrated that lincRNA-p21 acted as a tumor suppressive lncRNA in human hepatocellular carcinoma. We firstly found the downregulation of lincRNA-p21 level in human hepatocellular carcinoma tissues, and showed that low expression of lincRNA-p21 was associated with high disease stage and predicted poor survival.We showed that lincRNA-p21 knockdown promoted proliferation and colony formation of HepG2, Huh7 and Bel-7042 cells in vitro, while lincRNA-p21 overexpression obtained oppose results.We demonstrated that ER stress accounted for lincRNA-p21 effects on apoptosis, proliferation and in vivo growth of hepatocellular carcinoma. |
26305675 |
Lnc2Cancer
|
EL1397 |
TUC339 |
hepatocelluar carcinoma |
qPCR, knockdown etc. |
HCC tissue, cell lines (Hep3B, HepG2, PLC/PRF/5 etc.) |
up-regulated |
N/A |
The most highly significantly expressed ucRNA in HCC cell-derived extracellular vesicles was cloned and identified as a 1,198-bp ucRNA, termed TUC339. TUC339 was functionally implicated in modulating tumor cell growth and adhesion. Suppression of TUC339 by siRNA reduced HCC cell proliferation, clonogenic growth, and growth in soft agar. Thus, intercellular transfer of TUC339 represents a unique signaling mechanism by which tumor cells can promote HCC growth and spread. |
24167654 |
Lnc2Cancer
|
EL1399 |
TUG1 |
hepatocelluar carcinoma |
qPCR, Western blot, Luciferase reporter assay, knockdown, RIP etc. |
HCC tissue, cell lines (HepG2, MHCC-97H, Hep3B) |
up-regulated |
interaction |
TUG1 expression was up-regulated in HCC tissues and the higher expression of TUG1 was significantly correlated with tumor size and Barcelona Clinic Liver Cancer (BCLC) stage. Moreover, silencing of TUG1 expression inhibited HCC cell proliferation, colony formation, tumorigenicity and induced apoptosis in HCC cell lines. We also found that TUG1 overexpression was induced by nuclear transcription factor SP1 and TUG1 could epigeneticly repress Kruppel-like factor 2 (KLF2) transcription in HCC cells by binding with PRC2 and recruiting it to KLF2 promoter region. |
26336870 |
Lnc2Cancer
|
EL1402 |
TUSC7 |
hepatocelluar carcinoma |
N/A |
hepatocellular carcinoma |
down-regulated |
N/A |
inhibited cell metastasis, invasion, and epithelial-to-mesenchymal |
27002617 |
|
EL1417 |
uc001ncr |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
down-regulated |
expression |
We determined that a panel based on the expression of uc001ncr and AX800134 accurately diagnosed HBV-positive HCC (AUC values of 0.9494 and 0.9491 for the training and validation cohorts, respectively). The diagnostic performance of the panel remained high in patients with AFP>=400 ng/ml (AUC values of 0.9371 and 0.9527 for the training and validation cohorts, respectively). The panel also diagnosed early HCC (AUC values of 0.9450 and 0.9564 for the training and validation cohorts, respectively) |
26674525 |
Lnc2Cancer
|
EL1427 |
uc004bdv.3 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HBV-related HCC tissue |
up-regulated |
expression |
Four upregulated lncRNAs were randomly selected and analyzed for their expression levels in tissue samples from 14 HBV-related HCC patients. The corresponding non-tumor tissues were analyzed via qPCR, in which the obtained results are consistent with the microarray data. |
26109807 |
Lnc2Cancer
|
EL1431 |
UCA1 |
hepatocelluar carcinoma |
qPCR etc. |
HCC tissue |
up-regulated |
expression |
We found that lncRNA-UCA1 and lncRNA-WRAP53 were significantly higher in sera of HCC than those with chronic HCV infection or healthy volunteers. Our data suggested that the increased expression of UCA1 and WRAP53 was associated with advanced clinical parameters in HCC. |
26551349 |
Lnc2Cancer
|
EL1431 |
UCA1 |
hepatocelluar carcinoma |
qPCR, Western blot, knockdown, RIP etc. |
HCC tissue, cell lines (MHCC97L, SMMC7721, MHCC97H, HepG2, SK-Hep1 etc.) |
up-regulated |
N/A |
Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. |
25760077 |
LncRNADisease Lnc2Cancer
|
EL1435 |
UFC1 |
hepatocelluar carcinoma |
microarray, qPCR, in vitro knockdown etc. |
HCC tissue, cell lines (BEL-7402, SK-Hep1, Huh7, MHCC-97H) |
up-regulated |
regulation |
Levels of the lincRNA-UFC1 were increased in HCC tissues compared with controls, and associated with tumor size, Barcelona Clinic Liver Cancer stage, and patient outcomes. Transgenic expression of the lincRNA-UFC1 in HCC cells promoted their proliferation and cell-cycle progression and inhibited apoptosis, whereas short hairpin RNA knockdown of lincRNA-UFC1 had opposite effetcs. |
25449213 |
Lnc2Cancer
|
EL1438 |
ULK4P2 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HBV-related HCC tissue |
up-regulated |
interaction |
Four upregulated lncRNAs were randomly selected and analyzed for their expression levels in tissue samples from 14 HBV-related HCC patients. The corresponding non-tumor tissues were analyzed via qPCR, in which the obtained results are consistent with the microarray data. The upregulated large intergenic noncoding RNA ULK4P2 was physically combined with enhancer of zeste homolog 2. Therefore, the lncRNAs may participate in regulating HBV-related HCC. |
26109807 |
Lnc2Cancer
|
EL1439 |
URHC |
hepatocelluar carcinoma |
microarray, qPCR, Western blot etc. |
hepatocellular cancer tissue, cell lines (DMEM, Gibco, Gaithersburg, MD, USA etc.) |
up-regulated |
N/A |
We confirmed that URHC expression was up-regulated in 30 HCC cases (57.7%) and that its higher expression was correlated with poor overall survival. We further demonstrated that URHC inhibition reduced cell proliferation and promoted apoptosis. high URHC expression can promote cell proliferation and inhibit apoptosis by repressing ZAK expression through inactivation of the ERK/MAPK pathway. |
25013376 |
Lnc2Cancer
|
EL1444 |
VL30 LTRs |
hepatocelluar carcinoma |
N/A |
N/A |
N/A |
expression |
Trim24 (Tif1) and Trim33 (Tif1) interact to form a co-repressor complex that suppresses murine hepatocellular carcinoma. Here we show that Trim24 and Trim33 cooperatively repress retinoic acid receptor-dependent activity of VL30-class endogenous retroviruses (ERVs) in liver. In Trim24-knockout hepatocytes, VL30 derepression leads to accumulation of reverse-transcribed VL30 cDNA in the cytoplasm that correlates with activation of the viral-defense interferon responses mimicking the preneoplastic inflammatory state seen in human liver following exogenous viral infection. Furthermore, upon derepression, VL30 long terminal repeats (LTRs) act as promoter and enhancer elements deregulating expression of neighboring genes and generating enhancer RNAs that are required for LTR enhancer activity in hepatocytes in vivo. |
23377542 |
LncRNADisease
|
EL1446 |
VLDLR-AS1 |
hepatocelluar carcinoma |
qPCR, Western blot, knockdown etc. |
cell lines (HepG2, Hep3B, PLC/PRF-5, Huh-7) |
up-regulated |
N/A |
lincRNA-VLDLR (linc-VLDLR) was significantly upregulated in malignant hepatocytes. Exposure of HCC cells to diverse anticancer agents such as sorafenib, camptothecin, and doxorubicin increased linc-VLDLR expression in cells as well as within EVs released from these cells. Incubation with EVs reduced chemotherapy-induced cell death and also increased linc-VLDLR expression in recipient cells. RNAi-mediated knockdown of linc-VLDLR decreased cell viability and abrogated cell-cycle progression. |
24874432 |
Lnc2Cancer
|
EL1454 |
WRAP53 |
hepatocelluar carcinoma |
qPCR etc. |
HCC tissue |
up-regulated |
expression |
We found that lncRNA-UCA1 and lncRNA-WRAP53 were significantly higher in sera of HCC than those with chronic HCV infection or healthy volunteers. Our data suggested that the increased expression of UCA1 and WRAP53 was associated with advanced clinical parameters in HCC. |
26551349 |
Lnc2Cancer
|
EL1455 |
WSPAR |
hepatocelluar carcinoma |
microarray, qPCR, Northern blot, FISH etc. |
cell lines (Hep3B, Huh7, and PLC) |
up-regulated |
interaction |
Here, using transcriptome microarray analysis, we identified a long noncoding RNA (lncRNA) termed lncTCF7 that is highly expressed in HCC tumors and liver CSCs. Mechanistically, lncTCF7 recruits the SWI/SNF complex to the promoter of TCF7 to regulate its expression, leading to activation of Wnt signaling. Our data suggest that lncTCF7-mediated Wnt signaling primes liver CSC self-renewal and tumor propagation. |
25842979 |
Lnc2Cancer
|
EL1455 |
WSPAR |
hepatocelluar carcinoma |
qPCR, Western blot, Luciferase reporter assay etc. |
HCC cell lines (SK-Hep-1, BEL-7402) |
up-regulated |
interaction |
We demonstrate that IL-6 could induce lncTCF7 expression in a time- and dose-dependent manner, and we showed that IL-6 transcriptionally activated the expression of lncTCF7 in HCC cells by activating STAT3, a transcription activator which binds to promoter regions of lncTCF7. Furthermore, knocking-down STAT3 and inhibiting STAT3 activation reduced lncTCF7 expression. Importantly, RNA interference-based attenuation of lncTCF7 prevented IL-6-induced EMT and cell invasion. |
26452542 |
Lnc2Cancer
|
EL1456 |
WT1-AS |
hepatocelluar carcinoma |
qPCR, Western blot, Luciferase reporter assay etc. |
hepatocellular carcinoma tissue |
down-regulated |
interaction |
WT1-AS expression correlated negatively with WT1 expression in HCC tumor tissue. Kaplan-Meier curve analysis revealed that WT1-AS expression is a reliable indicator of HCC prognosis. The downregulation of WT1 expression by WT1-AS promoted cell apoptosis by suppressing the JAK/STAT3 signaling pathway. Bioinformatics analysis showed that WT1-AS downregulates WT1 by binding to the TATA region of the WT1 promotor. WT1-AS was also able to reverse WT1-mediated resistance to Dox based chemotherapy in HCC cells |
26462627 |
Lnc2Cancer
|
EL1502 |
XLOC_014172 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
up-regulated |
expression |
We discovered three lncRNA, RP11-160H22.5, XLOC_014172 and LOC149086, which were up-regulated in HCC comparing with the cancer-free controls. RP11-160H22.5, XLOC_014172 and LOC149086 might be the potential biomarker for the tumorigenesis prediction and XLOC_014172 and LOC149086 for metastasis prediction in the future. |
25714016 |
Lnc2Cancer
|
EL1515 |
ZEB1-AS1 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
up-regulated |
N/A |
The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. |
25025236 |
Lnc2Cancer
|
EL1515 |
ZEB1-AS1 |
hepatocelluar carcinoma |
microarray, qPCR, knockdown etc. |
HCC tissue, cell lines (Huh7, HepG2, etc.) |
up-regulated |
interaction |
We found that ZEB1-AS1 is frequently upregulated in HCC samples, especially in metastatic tumor tissues. ZEB1-AS1 promotes tumor growth and metastasis, acts as an oncogene in HCC. The ZEB1-AS1 gene is located in physical contiguity with ZEB1 and positively regulates the ZEB1 expression. ZEB1 inhibition partially abrogates ZEB1-AS1-induced epithelial to mesenchymal transition (EMT) and cancer metastasis. |
26073087 |
Lnc2Cancer
|
EL1517 |
ZFAS1 |
hepatocelluar carcinoma |
qPCR, Luciferase reporter assay, RIP etc. |
HCC tissue, cell lines (Huh7, HepG2, etc.) |
up-regulated |
interaction |
ZFAS1 functions as an oncogene in HCC progression by binding miR-150 and abrogating its tumor suppressive function in this setting. miR-150 repressed HCC cell invasion by inhibiting ZEB1 and the matrix metalloproteinases MMP14 and MMP16. Conversely, ZFAS1 activated ZEB1, MMP14 and MMP16 expression, inhibiting these effects of miR-150. |
26069248 |
Lnc2Cancer
|
EL1527 |
ZNF350-AS1 |
hepatocelluar carcinoma |
microarray, qPCR, RIP, RNA pulldown assay etc. |
HCC tissue |
up-regulated |
N/A |
AY129027, uc002pyc and DQ786243 were over-expressed in HCC, whereas the expression of AK055007 and AK123790 was decreased. |
21769904 |
Lnc2Cancer
|
EL1529 |
ZNF674-AS1 |
hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
up-regulated |
N/A |
The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. |
25025236 |
Lnc2Cancer
|
|